Starting April 21, you’ll be asked to log in or sign up for a free account after viewing 10 content pages each month.
Don’t worry—creating an account is quick and easy, and it comes with added benefits! Once logged in, you’ll not only continue accessing the content you already enjoy, but you’ll also unlock exclusive features like interactive donut plots for variant protein effects and variant impacts across the gene.
Stay tuned for these updates, and thank you for being part of our community!
Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | Lacutamab |
Synonyms | |
Therapy Description |
Lacutamab (IPH4102) is a monoclonal antibody that targets KIR3DL2, which potentially results in increased anti-tumor immune response against KIR3DL2-expressing tumor cells, and reduced tumor growth (PMID: 25361998, PMID: 31253572). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
Lacutamab | IPH-4102|IPH 4102|IPH4102 | Lacutamab (IPH4102) is a monoclonal antibody that targets KIR3DL2, which potentially results in increased anti-tumor immune response against KIR3DL2-expressing tumor cells, and reduced tumor growth (PMID: 25361998, PMID: 31253572). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT05321147 | Phase I | Lacutamab | Safety and Efficacy of Lacutamab in Patients With Relapsed/Refractory Peripheral T-cell Lymphoma That Express KIR3DL2 | Completed | USA | 1 |
NCT03902184 | Phase II | Gemcitabine + Lacutamab + Oxaliplatin Lacutamab | IPH4102 Alone or in Combination With Chemotherapy in Patients With Advanced T Cell Lymphoma (TELLOMAK) | Active, not recruiting | USA | POL | ITA | FRA | ESP | DEU | BEL | AUT | 0 |